Current Problems in Pediatrics 1992: Vol 22 Index

13 Pages·1992·4.3 MB·English

Volume 22, 1992
Index
A pediatricians minimizing risks, Allergenic extracts: causing
Aug. 299-300 anaphylaxis, Mar. 135-136
Abortion preventing exacerbation of Allergy: immunoglobulin in, IV, Sept.
recurrent, lV immunoglobulin in, problem, Aug. 299 345
Sept. 345 psychosocial problems of, Aug. Alloimmune thrombocytopenia: in
self-induced, during adolescence, 296 newborn, Sept. 373
Jan. 49 Statistics have not changed, Aug. Alport syndrome, Nov./Dec. 441
spontaneous, in cocaine with 295-296 Amblyomma americanum, Oct. 383
pregnancy, Aug. 309 interpretation of statistics has Amblyopia: binocular, vision in,
Abruptio placentae: in cocaine with changed, Aug. 296-298 May/June 245-246
pregnancy, Aug. 309 why adolescents get pregnant, Amenorrhea: lactational, for
Abuse Aug. 295-298 contraception, Nov./Dec. 452
child (see Child abuse) Advertising: cigarette, cost of, Anaphylaxis, Mar. 130-147
substance, maternal clinical clues Nov./Dec. 453 allergenic extracts causing, Mar.
to, Aug. 316 Advocacy 135-136
Acidosis: anion gap, with ketosis, child, May/June 215-221 commentary, Mar. 147
May/June 244 bad news, bad times, May/June diagnosis, differential, Mar. 138
Acquired immunodeficiency 215-216 drugs causing, Mar. 133-134
syndrome (see AIDS) grass roots cultivation, epidemiology, Mar. 130
Addiction: perinatal, state laws May/June 218-219 etiology, Mar. 132-137
regarding, Aug. 316 national debate, participating in, determination of, Mar. 140
Adenovirus: enteric, Jan. 53 learning to go the distance, exercise-induced, Mar. 137
Adolescence May/June 218 follow-up, long-term, Mar.
abortion during, self-induced, Jan. research, making it work for 140-142
49 advocates, May/June food additives causing, Mar. 133
AIDS risk exposure categories, 216-217 foods causing, Mar. 132-133
Apr. 169 smart politics, colleagues and foods triggering anaphylactic
drugs during, Feb. 60-62 coalitions, May/June reactions, Mar. 132
extremity during, lower, Jan. 217-218 idiopathic, Mar. 137
41-45 pediatric, as subspecialty, ingestants causing, Mar. 132—133
foot during, Jan. 44—45 May/June 219-220 insects causing, Mar. 133
health care in (see Health care in Advocate: pediatrician, role of, laboratory tests, Mar. 138
adolescents) May/June 220-221 latex, Oct. 417-418
health concerns in, July 252—253 Afipia felis, Nov./Dec. 456 management, immediate, Mar.
morbidity in, July 251-252 Age 138-140
mortality in, July 251-252 determination of, May/June 243 mast cell in
neurofibromatosis type 1 in, Feb. neurofibroma as function of, Feb. activation mechanisms, Mar.
91 90-91 130-131
orthopedics during, Jan. 37—45 at onset of retinopathy of mediator release stimuli, Mar.
premarital sexual activity of prematurity, Sept. 354 131-132
females, Feb. 60 Agenesis: lumbosacral, Jan. 18 medical procedures associated
sexual activity during, Feb. AIDS, Apr. 166-205 with, Mar. 136-137
59-60 in cocaine with pregnancy, Aug. pathology, Mar. 137-138
spine during, Jan. 37-41 308-309 pathophysiology, Mar. 130-132
Adolescent medicine immunoglobulin in, IV, Sept. prevention, Mar. 142
new resources in, Feb. 63—64 339-340 prognosis, Mar. 142
sex and drugs, Feb. 59-65 perinatally acquired, Apr. 167 proteins causing, serum, Mar. 136
as subspecialty, Feb. 63-64 risk exposure symptoms and signs, Mar. 137
Adolescent pregnancy, Aug. during adolescence, categories, triggering agents, avoidance of,
295-301 Apr. 169 Mar. 140-141
breaking the cycle of failure, Aug. children, categories, Apr. 168 Anemia: cognitive tests after,
300 female, categories, Apr. 167 May/June 236
as high risk, Aug. 298-299 in women, Apr. 167 Anesthesia: for circumcision,
critical importance of, Aug. 298 (See also HIV) Nov./Dec. 428
implications for intervention, Air bags, May/June 246 Angelman syndrome, Jan. 10
Aug. 298-299 Alice in Wonderland syndrome after Angioma: neurofibromatosis type 1,
medical problems of, Aug. 296 EBV, Aug. 328 Feb. 84
Current Problems in Pediatrics / November/December 1992 459
Index
Animal Welfare Act, May/June 242 Barlow’s test: in hip dysplasia, Jan. Buckle procedures: in retinopathy of
Anion gap acidosis: with ketosis, 19 prematurity, Sept. 367
May/June 244 Bartter syndrome: hypercaiciuric, Bunions: during adolescence, Jan. 45
Anomalies, Jan. 13 Nov./Dec. 445 Burns
Anomalies, congenital Behavior: neurofibromatosis type 1, hydrofluoric acid, July 286-287
in cocaine with pregnancy, Aug. Feb. 84-85 IV immunoglobulin in, Sept. 339
310-311 Biology: molecular, in Buttock: neurofibroma, Feb. 72
multifactorial, Jan. 4 neurofibromatosis, Feb. Bypass: cardiopulmonary, causing
in newborn, Jan. 14-16 96-99 anaphylaxis, Mar. 136-137
Antibiotics Biomedical research purposes: pets
in febrile infants, Mar. 150 for, May/June 242
in Giardia lamblia infection, Sept. Biopsy: of kidney, Nov./Dec. 442
376-377 Birth c
Antihypertensives: in defects, Nov./Dec. 452
glomerulonephritis, fracture, Jan. 16 Café au lait spots
poststreptococcal acute, of lower extremity, Jan. 18 in neurofibromatosis, Jan. 7
Nov./Dec. 433 HIV transmission during, Jan. 50 in neurofibromatosis type 1, Feb.
Antimicrobials: causing anaphylaxis, weights in retinopathy of 68
Mar. 134 prematurity, Sept. 351 Calcaneonavicular coalitions: during
Antiretroviral agents: in HIV-1, Apr. Bites: causing anaphylaxis, Mar. 133 adolescence, Jan. 45
193-194 Blindness: color, Mar. 149 Calcaneovalgus foot, Jan. 23
Apheresis: causing anaphylaxis, Blood pressure Camptodactyly, Jan. 15
Mar. 136 high, identifying children with, July Campylobacter jejuni, Mar. 150
Apnea 265 Cancer, Feb. 78
after diphtheria-pertussis-tetanus high and low, Nov./Dec. 454 cervical, and circumcision,
immunizations, May/June 242 measurement in boys, July Nov./Dec. 427
in child exposed to cocaine in 262-263 occupation and, Mar. 151
pregnancy, Aug. 312 measurement in girls, July penis, and circumcision, Nov./Dec.
Appendicitis: suspected, rectal 261-262 427
examination in, Sept. 372 normal, July 262—263 Candida: causing esophagitis, Apr.
Arterial tree: in neurofibromatosis tracking, July 264 183
type 1, Feb. 82 variability, factors in, July Car safety seat: complications from,
Arteriography: in neurofibromatosis, — 264 Apr. 207-208
Feb. 95 Blount’s disease: in toddler, Carbon monoxide poisoning, Aug.
Arthritis Jan. 31 328-329
rheumatoid, juvenile, Feb. 110 Body size: and blood pressure Cardiology, preventive, July
septic (see Septic arthritis) variability, July 263-264 258-281
Asphyxiation: after “baby cushions,” Bone cyst: juvenile, Jan. 32 commentary, July 282
Mar. 148 Bow leg Cardiopulmonary bypass: causing
Asthma: refractory chronic, Oct. during adolescence, Jan. 43 anaphylaxis, Mar. 136-137
418-419 physiologic, in toddler, Jan. 30 Cardiovascular
Athletes: concussion in, Apr. 208 Bowing disease, premature, and
Audiogram: neurofibromatosis type in neurofibromatosis type 1, Feb. low-density lipoproteins, July
1, Feb. 87 80 273
Avocados: bananas and rubber of tibia (see Tibia, bowing) findings in HIV-1, Apr. 190-191
gloves, Oct. 417 Brachial plexus palsy: obstetric, Jan. fitness and physical activity, July
15-16 276-278
Brain Health Schedule, July 259
development, role of nutrition in, health schedule, July 261-262
May/June 228-229 with activity level increase, July
tumors, growth hormone in, Oct. 277-278
Back pain: during adolescence, Jan. 407 cholesterol management and,
41 Breast integrated, July 273-274
Bacterial infections: IV development, Tanner stages in coronary heart disease in family
immunoglobulin in, Sept. 340 girls, Oct. 394 history and, July 276-278
Baker's popliteal cyst, Jan. 35-36 feeding hypertension diagnosis and, July
Balanitis: and circumcision, cocaine and, Aug. 316 266
Nov./Dec. 427 infectious mononucleosis and, obesity prevention and, July 279
Balloon July 283-284 smoking prevention and,
catheter, Sept. 372 phenylketonuria newborn integrated, July 275-276
pulmonary valvuloplasty, Aug. screening and, Apr. 164 Cat-scratch disease, Nov./Dec. 456
326-327 Breathing patterns: in prematurity, Catheter: balloon, Sept. 372
Bananas: rubber gloves and Sept. 350 Cavus foot: during adolescence, Jan.
avocados, Oct. 417 Buccal pad neurofibroma, Feb. 71 45
460 Current Problems in Pediatrics / November/December 1992
Index
Cell Chromosomes: translocation methodologic issues, Aug.
mast (see Mast cell) between “black” and 306-307
Schwann, neurofibromatosis type “hatched,” Jan. 9 neonatal implications, Aug.
1, Feb. 82 Cigarette advertising: cost of, 310-313
spindle, neurofibromatosis type 1, Nov./Dec. 453 neurobehavioral deficiencies in
Feb. 82 Circumcision, Nov./Dec. 424-431 child, Aug. 312-313
Centipede ingestion, Mar. 153 anesthesia for, Nov./Dec. 428 number of newborn with positive
Central nervous system: in HIV-1, balanitis and, Nov./Dec. 427 findings on urine toxicology,
Apr. 186-187 cervical cancer and, Nov./Dec. Aug. 303
Cerebral 427 obstetric perspectives, Aug.
infarction in child exposed to complications, Nov./Dec. 307-310
cocaine in pregnancy, Aug. 428-429 pathophysiology, Aug. 304-307
311-312 frequency rate, Nov./Dec. 426 possible effects, direct and
palsy in toddler, Jan. 24 penile cancer and, Nov./Dec. 427 indirect pathways, Aug. 306
Cerebrovascular disease: penile hygiene in, Nov./Dec. 429 preterm labor in, Aug. 310
neurofibromatosis type 1, Feb. posthitis and, Nov./Dec. 427 prevalence, Aug. 304
83 risks, Nov./Dec. 428-429 psychosocial issues, Aug.
Cervical sexually transmissible diseases 307-308
cancer and circumcision, and, Nov./Dec. 426-427 role of pediatrician in, Aug.
Nov./Dec. 427 urinary tract infections and, 317-318
instability in toddler, Jan. 27 Nov./Dec. 424-426 sudden infant death syndrome
Charcoal, activated in Clinodactyly, Jan. 15 in, Aug. 312
gastrointestinal Clubfoot, Jan. 21-22 syphilis in, Aug. 308
decontamination (see Clubhand vascular defects in child,
Gastrointestinal radial, Jan. 14-15 Aug. 311
decontamination, activated ulnar, Jan. 15 toxicologic testing of newborn,
charcoal in) Cocaine Aug. 316-317
Cheek: neurofibroma of, Feb. 71 breast-feeding and, Aug. 316 Cognitive
Chemotherapy Clinical effects on adult user, Aug. abilities, neurofibromatosis type 1,
anaphylaxis due to, Mar. 134 305 Feb. 87
of optic pathway glioma, Feb. 77 exposed infants, long-term tests after anemia, May/June 236
Chickenpox: drugs for, Apr. outcome, Aug. 313-315 Collagen vascular disease: IV
206-207 intoxication, Mar. 119-121 immunoglobulin in, Sept. 345
Child fetal effects, Mar. 120-121 Color blindness, Mar. 149
abuse high-risk groups, Mar. 119-120 Computed tomography
in cocaine with pregnancy, Aug. implications, Mar. 121 in neurofibromatosis, Feb. 95
315-316 new Clinical syndromes, Mar. of optic nerve glioma, Feb. 74
issues in, Aug. 315-316 121 Computerized neuroimaging: in
risk, interactive and interrelated prevalence, Mar. 119 neurofibromatosis, Feb.
issues in, Aug. 315 maternal, Apr. 209 95-96
of toddler, Jan. 24-25 metabolites, screening for, Sept. Concussion: in athletes, Apr. 208
advocacy (see Advocacy, child) 374 Confusion and disorientation, Aug.
growing, cocaine and pregnancy, with pregnancy, Aug. 302-322 328
Aug. 302-322 abnormal growth patterns in Congenital anomalies (see
Children child, Aug. 310 Anomalies, congenital)
orthopedics for (see Orthopedics) abortion in, spontaneous, Aug. Constipation: and cri du chat
sixty nine born to one mother, Jan. 309 syndrome, Feb. 109-110
54, 55 abruptio placentae in, Aug. 309 Constriction bands, Jan. 14
Cholesterol AIDS in, Aug. 308-309 Contraception: lactational
Education Program, National, July anomalies in child, congenital, amenorrhea for, Nov./Dec.
271-273 Aug. 310-311 452
individualized approach, July apnea in child, Aug. 312 Contracture: femoral rotation, in
271-273 cerebral infarction in child, Aug. toddler, Jan. 29
population approach, July 271 311-312 Contrast media: iodinated, causing
screening approach, July 272 commentary, Aug. 322 anaphylaxis, Mar. 135
management, integrated, and complications, infectious, Aug. Convulsions: neurofibromatosis type
cardiovascular health 308-309 1, Feb. 83
schedule, July 273-274 complications, obstetric, Aug. Coronary heart disease
metabolism, normal, July 267 309-310 family history, July 276
relationship to coronary heart epidemiology, Aug. 302-307 cardiovascular health schedule
disease, July 266 growing child and, Aug. and, July 276
in Zen monk, Nov./Dec. 454 302-322 incidence, July 267
Chondromalacia: of patella during intrauterine growth retardation relationship to cholesterol, July
adolescence, Jan. 43 in, Aug. 309-310 266
Current Problems in Pediatrics / November/December 1992 461
Index
Corticosteroids disposable, Sept. 375
in glomerular disease, Nov./Dec. used before toilet training, Feb.
434 112 Eating: child who won't eat,
in glomerulonephritis, Diarrhea: in HIV-1, Apr. 188 May/June 231
complications, Nov./Dec. 434 Diet Elbow
Cost control loss and IQ in abnormalities, in newborn,
of — advertising, Nov./Dec. phenylketonuria, Apr. 162 Jan. 15
4 food-restricted, and anaphylaxis, nursemaid’s, Jan. 26
of immune globulin, Jan. 51 Mar. 141 Electroencephalography:
of phenylketonuria newborn vegetarian, May/June 236-238 neurofibromatosis type 1, Feb.
screening, Apr. 164 Zen macrobiotic, May/June 238 87
Counseling parents: in retinopathy of Dietary allowances, recommended, Electromyography: neurofibromatosis
prematurity, Sept. 357-361 May/June 231 type 1, Feb. 86
Craniofacial dysplasia: in current, May/June 231-233 Encephalitis: Western equine, Mar.
neurofibromatosis type 1, Feb. Diphtheria immunization: in apnea, 154
81 May/June 242 Encephalopathy: in HIV-1, Apr. 187
Cri du chat syndrome, Feb. 109-110 Dipylidium caninum infection, Sept. Endocrinology: and the presidential
Criminal law: lengthiest trial in, Apr. 372 race, Nov./Dec. 455
210 Discitis: juvenile, Jan. 33-34 Enema: causing anaphylaxis, Mar.
Crying: and gastroesophageal reflux, Dislocation 137
Aug. 326 knee, congenital, Jan. 20 Enteropathy: protein-losing, IV
Cryotherapy: in retinopathy of patella during adolescence, Jan. immunoglobulin in, Sept. 338
prematurity, Sept. 365-366 43 Enuresis, Apr. 210
Cyst radial head, congenital, Jan. 15 daytime, causes, Sept. 376
Baker's popliteal, Jan. 35-36 Disomy: uniparental, Jan. 8-9 “Enuresis risoria,” Sept. 375
bone, juvenile, Jan. 32 Disorientation and confusion, Aug. Enzymes: gastrointestinal, and
Cystic 328 weaning, May/June 228
fibrosis, heart-lung transplant in, DMSA in lead poisoning (see Lead Ependymoma, Feb. 77
Mar. 152-153 poisoning, DMSA in) Epstein-Barr virus
kidney disorders, Nov./Dec. DNA: and oil, Arabian crude, Oct. Alice in Wonderland syndrome
445-448 417 and, Aug. 328
Cystinosis, Nov./Dec. 441 IV immunoglobulin in, Sept. 342
Cytomegalovirus bites, Feb. 111-112 Erythrocyte sedimentation rate: and
congenital, ganciclovir for, Oct. tapeworm, Sept. 372 obesity, Apr. 209-210
415 Drinking age, Sept. 373 Esophagitis: due to Candida, Apr.
IV immunoglobulin in, Sept. Drugs 183
341-342 anaphylaxis due to, Mar. 133-134 Ethanol toxicology, July 287
for chickenpox, Apr. 206-207 Ethics: ethics everywhere, Nov./Dec.
illicit 422-423
during adolescence, Feb. Etretinate, Mar. 149
60-62 Ewing's sarcoma: juvenile, Jan. 33
Dactinomycin: and heart defects in sex and adolescent medicine, Exercise-induced anaphylaxis, Mar.
Offspring, Feb. 111 Feb. 59-65 137
Debt: of medical students, Mar. implicated in tubulointerstitial Extremity
149-150 nephritis, Nov./Dec. 440 lower
Deer: transmitting infection to Pneumocystis carinii pneumonia, during adolescence, Jan. 41—45
humans, May/June 246-247 Apr. 180-181 juvenile, Jan. 34-37
Deformity (see Anomalies) with renal toxicity in HIV-1, Apr. in neurofibromatosis type 1,
Dentist: hepatitis C virus in, Apr. 206 190 radiography of, Feb. 79
Dermatologic manifestations: in Duke's disease, Aug. 323 newborn, Jan. 18-23
HIV-1, Apr. 191 Dwarfism: pituitary, of Richard Ill, upper
Developmental abnormalities: in Mar. 149 in newborn, Jan. 14-16
HIV-1, Apr. 186-187 Dysplasia proximal part neurofibroma, Feb.
Developmental delay craniofacial, in neurofibromatosis 72
neurofibromatosis type 1, Feb. 85 type 1, Feb. 81 in toddier, Jan. 26-27
in toddler, Jan. 24 of hip (see Hip, dysplasia)
Diabetes insipidus: nephrogenic, multicystic, of kidney, Nov./Dec.
Nov./Dec. 443-445 445-446 F
Diagnostic agents: causing in neurofibromatosis type 1, Feb.
anaphylaxis, Mar. 134 Face: neurofibroma of, Feb. 71
Dialysis: causing anaphylaxis, Mar. sphenoid wing, Feb. 81 Falling child: toddler, Jan. 24
136 vascular, in neurofibromatosis type Falls, July 283
Diapers, Nov./Dec. 457 1, Feb. 82-83 in children, Sept. 374
costs of, Feb. 112 vertebra, Feb. 81 Fanconi syndrome, Nov./Dec. 442
462 Current Problems in Pediatrics / November/December 1992
Index
Feeding: Sackett’s feeding schedule, Fourth disease, Aug. 323 Genital development: Tanner stages
May/June 227 Fracture in boys, Oct. 393
Feet (see Foot) birth, Jan. 16 Genitalia: names for, May/June
Femur of lower extremity, Jan. 18 245
anteversion in toddler, Jan. forearm, in toddler, Jan. 26—27 Genomic imprinting, Jan. 8—11
29-30 Freckling: in neurofibromatosis type neurofibromatosis, Feb. 95
contracture, rotation, in toddler, 1, Feb. 68 Gestational age: correlation with
Jan. 29 Fungal infections: in HIV-1, Apr. positive obstetric
deficiency syndromes, Jan. 23 183-184 performance, Oct. 413
epiphysis, slipped capital, Jan. Giardia lamblia infection: antibiotics
41-42 in, Sept. 376-377
torsion in toddler, Jan. 29 G Glioma: optic pathway (see Optic
Fetus pathway glioma)
effects of maternal cocaine Gallstones, Nov./Dec. 453 Glomerular
intoxication on, Mar. 120-121 Ganciclovir: for cytomegalovirus, crescent in rapidly progressive
growth, factors that adversely congenital, Oct. 415 glomerulonephritis, Nov./Dec.
affect, Oct. 391 Gastric lavage: in gastrointestinal 437
handedness, Jan. 49-50 decontamination, Mar. disease, corticosteroids in,
maternal-fetal transmission of 122-123 Nov./Dec. 434
Lyme disease, Oct. 385 Gastroenterologist: hepatitis C virus disorders, congenital, Nov./Dec.
Fibroplasia: retrolental, Sept. in, Apr. 206 440-441
349-351 Gastroesophageal reflux: and crying, Glomerulonephritis
Fibrosis: cystic, heart-lung transplant Aug. 326 corticosteroids in, complications,
in, Mar. 152-153 Gastrointestinal decontamination, Nov./Dec. 434
Fibrous cortical defects, Jan. 32 Mar. 121-125 hypocomplementemia and,
Fibula: deficiencies in newborn, Jan. activated charcoal for, Mar. 123 Nov./Dec. 433
efficacy in overdose setting, membranoproliferative, Nov./Dec.
Fingerstick device: spring-loaded, Mar. 123-124 433-435
problems with, Oct. 415-416 implications, Mar. 125 poststreptococcal acute, Nov./Dec.
Fire hydrants: playing with, Feb. 108 ipecac vs. lavage 432-433
Fishhook removal: latest in, Oct. early studies, Mar. 121-122 progressive, rapidly, Nov./Dec.
416-417 efficacy in overdose setting, 437-438
Flatfoot Mar. 123-124 glomerular crescent in,
during adolescence, Jan. 45 gastric, later studies, Mar. Nov./Dec. 437
in toddler, Jan. 31 122-123 in systemic disease, Nov./Dec.
Fluorosis, July 287-288 observation for “minimally 438-439
Food symptomatic” patients, Mar. Glomerulopathy: primary, Nov./Dec.
additives causing anaphylaxis, 124 432-438
Mar. 133 Gastrointestinal enzymes: and Glomus tumor gene: pedigree from
anaphylaxis due to, Mar. 132—133 weaning, May/June 228 family, Jan. 11
iron absorption from, May/June Gastrointestinal problems: in HIV-1, Gloves: rubber, bananas and
234 Apr. 187-188 avocados, Oct. 417
semisolid and solid, proper age to Gastrointestinal vascular Growing pains, Jan. 36
start, approach to, May/June compromise: Growth
227-228 neurofibromatosis type 1, Feb. cartilage-hypothalamic-pituitary
surveys in U.S., May/June 233 83-84 axis, Oct. 398
Foot Gene chart for height and weight in girls,
during adolescence, Jan. 44-45 glomus tumor, pedigree from Oct. 395
calcaneovaigus, Jan. 23 family, Jan. 11 considerations for practicing
cavus, during adolescence, Jan. mitochondrial and inheritance, Jan. pediatrician, Oct. 390-412
45 4-6 factor
clubfoot, Jan. 21-22 neurofibromatosis type 1 (see epidermal family, Oct. 401
flatfoot Neurofibromatosis type 1 platelet-derived family, Oct. 401
during adolescence, Jan. 45 gene) transforming beta family, Oct.
in toddler, Jan. 31 Genetic counseling (see 401
neurofibroma, Feb. 72 Neurofibromatosis genetic factors, families of, Oct. 401
rocker-bottom, Jan. 22—23 counseling) fetus, factors that adversely affect,
Footwear type: vs. footing loss, July Genetics Oct. 391
283 blood pressure variability and, July hormone
Forearm 264 considerations for practicing
fracture in toddler, Jan. 26—27 in neurofibromatosis type 1 (see pediatrician, Oct. 390-412
neurofibroma, Feb. 72 Neurofibromatosis type 1, deficiency, etiology of, Oct. 405
Fossae: supraclavicular, genetics) increasing during male puberty,
neurofibroma, Feb. 72 (See also Inheritance) Oct. 394
Current Problems in Pediatrics / November/December 1992 463
Growth Continued Height encephalopathy in, Apr. 187
levels, serum, clinical growth chart for, in girls, Oct. 395 epidemiology, Apr. 166-168
evaluation, Oct. 403-404 in neurofibromatosis type 1, Feb. health issues in, psychosocial and
nontraditional uses, Oct. 78-79 public, Apr. 195-196
406-407 over eight feet, Jan. 54 immunologic abnormalities in, Apr.
pituitary-derived vs. of presidents, Nov./Dec. 455 176-177
recombinant, Oct. 402-403 Tanner-Davies chart for girls, Oct. infections
secretion, physiology of, Oct. 396 antiretroviral agents in, Apr.
398-400 Tanner-Davies height velocity, for 193-194
serum concentrations after girls, Oct. 396 bacterial, Apr. 177-179
subcutaneous administration, Helicobacter pylori: relationship to cardiovascular findings, Apr.
Oct. 405 MALT lymphoma, Oct. 190-191
testing, choice of who should be 414-415 classification summary, Apr. 176
tested and why, Oct. 408 Hematologic CNS in, Apr. 186-187
theoretical considerations, Oct. abnormalities in HIV-1, Apr. complications with, Apr.
407-408 191-192 177-186
treatment, choice of patient, Oct. disease, IV immunoglobulin in, definition, Apr. 173
407-408 Sept. 344-345 dermatologic manifestations in,
pattern abnormalities in child in disorders, IV immunoglobulin in, Apr. 191
cocaine with pregnancy, Aug. Sept. 338 developmental abnormalities in,
310 Hemiparesis: neurofibromatosis type Apr. 186-187
retardation, causes of, Oct. 395 1, Feb. 83 diarrhea in, Apr. 188
role in primary pediatric health Hemolytic-uremic syndrome, fungal, Apr. 183-184
care provider, Oct. 393-404 Nov./Dec. 439-440 gastrointestinal problems in,
system as only mechanism by IV immunoglobulin in, Sept. 345 Apr. 187-188
growth is controlled in Henoch-Schénlein purpura, hematologic abnormalities in,
humans, Oct. 408 Nov./Dec. 438-439 Apr. 191-192
Guillain-Barré syndrome, Mar. 150 Hepatitis virus, Jan. 53 immunizations, Apr. 184—186
Gum disease: relationship to C, in gastroenterologist and maternal, and outpatient
spirochetes, Oct. 413-414 dentist, Apr. 206 follow-up of infants, Apr. 175
Gun: shotgun injuries, Mar. 154 Heterodisomy, Jan. 8 nephrologic abnormalities in,
Hickey: 2-fathom, Oct. 413 Apr. 189-190
Hip nutritional problems in, Apr.
H dysplasia, congenital, Jan. 18 187-188
dysplasia, developmental, Jan. otorhinolaryngologic
Hamartoma, Feb. 77 18-20 complications, Apr. 188-189
Hand Barlow's test in, Jan. 19 parasitic, Apr. 184
absent rays, Jan. 15 confirmatory test, Jan. 19 prevention, Apr. 193-195
neurofibroma, Feb. 72 diagnosis, differential, Jan. 19—20 prognosis, Apr. 194-195
Handedness: fetal, Jan. 49-50 Ortolani’s test in, Jan. 19 renal toxicity in, drugs
Happy Puppet syndrome, Jan. 10 in toddler, Jan. 27-28 associated with, Apr. 190
Head injuries: sports-related, in treatment, Jan. 20 treatment, Apr. 193-195
Scotland, Mar. 148-149 dysplasia, during adolescence, tumors associated with, Apr.
Health Jan. 42 192
care in adolescents, July 251-257 septic, in toddler, Jan. 28-29 viral, Apr. 181-183
accessibility of, July 253-254 HIV, Apr. 166-205 manifestations, clinical,
role of pediatrician in, July detection with polymerase chain management, Apr. 176-192
254-255 reaction, Apr. 175 pathogenesis, Apr. 168-170
concerns in adolescents, July immune globulin and, Jan. 50-51 Pneumocystis carinii pneumonia
252-253 maternal, in Scotland, Feb. 109 (see Pneumocystis carinii
issues, psychosocial and public, in 1 (see below) pneumonia in HIV-1)
HIV-1, Apr. 195-196 positive in Job Corps, July pneumonitis in, lymphoid
Hearing 285-286 interstitial, Apr. 186
neurofibromatosis type 1, Feb. 86 risks in twins, Aug. 326 schematic representation, Apr. 170
in otitis media and nose blowing, transmission signs and symptoms, early
July 285 during birth, Jan. 50 recognition, Apr. 176
Heart during pregnancy, Jan. 50 transmission, vertical, Apr.
defects in offspring after during wrestling, Aug. 325 170-172
dactinomycin, Feb. 111 (See also AIDS) prevention, Apr. 194
disease, coronary (see Coronary HIV-1, Apr. 166-205 rates, Apr. 170
heart disease) commentary, Apr. 205 rates, factors potentially
Healthy Heart Profile, July 260 diagnosis, laboratory, Apr. affecting, Apr. 171
lung transplant: in cystic fibrosis, 172-175 vaccines, Apr. 194
Mar. 152-153 tools for, Apr. 173 Western biot preparation, Apr. 174
464 Current Problems in Pediatrics / November/December 1992
Index
Hormone, growth (see Growth in collagen vascular disease, Sept. Intellectual performance:
hormone) 345 neurofibromatosis type 1, Feb.
Hydrofluoric acid burns, July in cytomegalovirus, Sept. 341-342 84-85
286-287 enteropathy, protein-losing, Sept. Intoxication, cocaine (see Cocaine
Hyperapo-B-lipoproteinemia: with 338 intoxication)
hyperlipidemia, familial, July in Epstein-Barr virus, Sept. 342 Intracranial tumors, Feb. 77
270 future directions of, Sept. 345 Intrauterine growth retardation: with
Hypercalciuric Bartter syndrome, in hematologic disease, Sept. cocaine in pregnancy, Aug.
Nov./Dec. 445 344-345 309-310
Hypercholesterolemia, July 268-271 in hematologic disorders, Sept. Ipecac
familial, July 269-270 338 in gastrointestinal decontamination
lipoproteins in, low-density, July in hemolytic-uremic syndrome, (see Gastrointestinal
273 Sept. 345 decontamination, ipecac)
secondary, causes of, July 269 in immunodeficiencies, primary, pseudo-melanosis coli and, July
Hyperlipidemia: with Sept. 337-340 288
hyperapo-B- in immunoregulatory diseases, 1Q: in phenylketonuria and diet
lipoproteinemia, Sept. 342-345 control loss, Apr. 162
familial, July 270 in Kawasaki disease, Sept. 344 Iris Lisch nodules: in
Hyperoxaluria, Nov./Dec. 442-443 licensed in U.S., Sept. 336 neurofibromatosis type 1, Feb.
Hyperphenylalaninemias: common, in nephrotic syndrome, Sept. 338 67-69
differential diagnosis, Apr. 161 in neurologic disease, Sept. 344 lron
Hypertension, July 262-266 in oncologic disorders, Sept. 338 absorption from foods, May/June
diagnosis, July 264-265 in parvovirus, Sept. 342 234
cardiovascular health schedule, pharmacology, Sept. 335-337 deficiency
July 266 in prematurity, Sept. 339 nutritional aspects of, May/June
treatment, July 265-266 in purpura, immune 234
white coat, July 289 thrombocytopenic, Sept. 343 stages of, May/June 234-235
Hypocomplementemia: and in respiratory syncytial virus, Sept. in human vs. cow’s milk and
glomerulonephritis, Nov./Dec. 342 formula, May/June 235-236
433 in sepsis in newborn, Sept. Isodisomy, Jan. 8
Hypophosphatemic rickets: X-linked, 340-341 Ixodes dammini, Oct. 383
Nov./Dec. 443 in surgery, Sept. 338
Hypopituitarism in transplantation period, Sept.
etiology, Oct. 405 339 J
treatment, Oct. 404-406 in trauma, Sept. 338
Hypothalamic-pituitary-growth in varicella, Sept. 342 Job Corps: and HIV positive, July
cartilage axis, Oct. 398 in viral infections, Sept. 341-342 285-286
Immunologic abnormalities: in HIV-1, Juvenile
Apr. 176-177 extremity, lower, Jan. 34-37
immunoregulatory diseases: IV orthopedic problems, Jan. 32-37
immunoglobulin in, Sept. spine, Jan. 33-34
Ig (see Immunoglobulin) 342-345
llizarov procedure, Feb. 79 Imprinting: genomic, Jan. 8—11
Immune globulin Infarction: cerebral, in child exposed K
contraindications, Jan. 51 to cocaine in pregnancy, Aug.
cost of, Jan. 51 311-312 Kawasaki disease: IV
HIV and, Jan. 50-51 Infectious mononucleosis: in breast immunoglobulin in, Sept. 344
Immunizations feeding, July 283-284 Ketosis: with anion gap acidosis,
diphtheria-pertussis-tetanus, Ingestants: producing anaphylaxis, May/June 244
apnea after, May/June 242 Mar. 132-133 Kidney
in HIV-1, Apr. 184-186 Inheritance biopsy, Nov./Dec. 442
Immunodeficiencies genomic imprinting, Jan. 8—11 cystic, disorders, Nov./Dec.
primary, IV immunoglobulin in, mitochondrial genes and, Jan. 445-448
Sept. 337-340 4-6 cystic, medullary, Nov./Dec. 446
secondary, IV immunoglobulin in, mosaicism, Jan. 6-8 diseases, Nov./Dec. 432-451
Sept. 338 multifactorial, Jan. 3-4 failure, growth hormone in, Oct.
Immunoglobulin: A nephropathy, nonmendelian, Jan. 3-12 406
Nov./Dec. 435 (See also Genetics) immaturity and weaning, May/June
immunoglobulin, IV, Sept. 335-348 Insects: causing anaphylaxis, Mar. 228
in abortion, recurrent, Sept. 345 133 metabolic disorders involving,
in AIDS, Sept. 339-340 Inspection: in orthopedics, Jan. 13 congenital, Nov./Dec.
in allergic diseases, Sept. 345 Insurance: hospital resource 441-445
in bacterial infections, Sept. 340 allocation and sick newborn, multicystic dysplasia, Nov./Dec.
in burns, Sept. 339 July 289 445-446
465
Current Problems in Pediatrics / November/December 1992
Index
Kidney Continued Leukemia, Feb. 78
polycystic (see Polycystic kidney growth hormone in, Oct. 407
disease) risk factors for, July 288 Macrocephaly in neurofibromatosis,
toxicity from drugs in HIV-1, Apr. Leukocytosis: extreme, Feb. 113 Feb. 82
190 Light exposure: in retinopathy of type 1, Feb. 78-79
Klippel-Feil syndrome, Jan. 16 prematurity, Sept. 364 Macromolecules: causing
Knee Lipids, July 266-274 anaphylaxis, Mar. 134
angular deformities in toddler, Jan. concentrations, normal plasma, Magnetic resonance imaging: in
30-31 July 268 neurofibromatosis, Feb. 95
dislocation, congenital, Jan. 20 levels in childhood, July 267-268 MALT lymphoma: relationship to
knock Lipoproteins Helicobacter pylori, Oct.
during adolescence, Jan. 42—43 concentrations, normal plasma, 414-415
physiologic, in toddler, Jan. 31 July 268 Maple syrup urine disease:
pain during adolescence, Jan. 43 excess, familial, July 270-271 incidence, Apr. 211
Knock knee (see Knee, knock) low-density Marijuana: metabolites of, screening
Kyphosis Classification, education and for, Sept. 374
during adolescence, Jan. 38-39 follow-up, July 273 Marrow, May/June 243-244
congenital, Jan. 17 in hypercholesterolemia and Mast cell
postural, during adolescence, Jan. premature cardiovascular in anaphylaxis (see Anaphylaxis,
disease, July 273 mast cell in)
Scheuermann’s, during Lisch nodules: of iris in mediator release from, substances
adolescence, Jan. 39-40 neurofibromatosis type 1, Feb. producing, Mar. 131
68 Measles: in gymnasts, Aug. 325
Lordosis: lumbar, juvenile, Jan. 34 Mediastinum: neurofibroma, Feb. 72
L Lumbar lordosis: juvenile, Jan. 34 Medical students: debt of, Mar.
Lumbosacral agenesis, Jan. 18 149-150
Labor: preterm, with cocaine in Lung Medicine, adolescent (see
pregnancy, Aug. 310 heart transplant, in cystic fibrosis, Adolescent medicine)
Lactational amenorrhea: for Mar. 152-153 Meduloblastoma, Feb. 77
contraception, Nov./Dec. 452 valvuloplasty, balloon, Aug. Melanoma: malignant, Nov./Dec. 454
Landfill: Fresh Kill, on Staten Island, 326-327 Meningeal defects: in
Sept. 375 Lupus erythematosus: systemic, neurofibromatosis type 1, Feb.
Latex anaphylaxis, Oct. 417-418 Nov./Dec. 438 81
Laughter: pathologic, Sept. 375 Lyme disease, Oct. 383-389 Meningioma, Feb. 77
Lavage in gastrointestinal in Antarctic, Nov./Dec. 457 Metabolic disorders: congenital,
decontamination (see antibody testing not helpful in early involving kidney, Nov./Dec.
Gastrointestinal disease, Oct. 387 441-445
decontamination, ipecac vs. causative organism, Oct. 383-384 Metatarsus adductus, Jan. 23
lavage) Clinical manifestations, Oct. 384 Microsporum canis, Feb. 111
Laws diagnosis Microwave ovens: risks with, Apr.
criminal, lengthiest trial in, Apr. differential, Oct. 385-386 211-212
210 specific, Oct. 386-387 Milk: human, frozen for storage,
seat belt, efficacy of, Apr. 207 early Nov./Dec. 456-457
of state regarding perinatal disseminated disease, Oct. Millipede: distinguished from
addiction, Aug. 316 384-385 centipede, Mar. 153
Lead poisoning, Feb. 109 localized disease, Oct. 384 Mitochondrial
DMSA in, Mar. 125-127 epidemiology, Oct. 383-384 genes and inheritance, Jan. 4-6
adverse effects, Mar. 127 late infection, Oct. 385-389 inheritance of disorder, pedigree,
contraindications, Mar. 127 late manifestations, Oct. 387 Jan. 5
implications, Mar. 127 maternal-fetal transmission, Oct. Molecular biology: in
indications, Mar. 126-127 385 neurofibromatosis, Feb.
pharmacology, Mar. 126 in poodle, Jan. 51-52 96-99
uses, Mar. 126-127 prevention, Oct. 388 Mononucleosis: in breast-feeding,
history of, Mar. 125-126 symptoms, vague nonspecific, Oct. July 283-284
identification of, Mar. 125-126 387 Morbidity: in adolescents, July
Learning abilities: neurofibromatosis treatment, Oct. 387-388 251-252
type 1, Feb. 87 Lymphocyte counts: age-adjusted Morgan angioma: neurofibromatosis
Left-handedness: and situs inversus, normal, Apr. 177 type 1, Feb. 84
Aug. 327 Lymphoid interstitial pneumonitis: in Mortality: in adolescents, July
Leg HIV-1, Apr. 186 251-252
bow, during adolescence, Jan. 43 Lymphoma: MALT, relationship to Mosaicism, Jan. 6-8
length discrepancy, Jan. 36-37 Helicobacter pylori, Oct. Motor function abnormalities:
neurofibroma, Feb. 72 414-415 neurofibromatosis type 1, Feb.
Legg-Calvé-Perthes disease, Jan. 34 Lysol spray: and rotavirus, Aug. 323 85-86
466 Current Problems in Pediatrics / November/December 1992
Index
Movement: neurofibromatosis type 1, neck, Feb. 71-72 mutation rate, Feb. 92
Feb. 85-86 oral, Feb. 71 paternal effect, Feb. 92-93
Muscle orbit and, Feb. 71 histories in, Feb. 87
strength in orthopedics, Jan. 14 paraspinal, Feb. 77 iris Lisch nodules in, Feb. 68
torticollis, congenital, Jan. 16-17 pelvis, Feb. 72 mild, Feb. 87
Mutation rate: neurofibromatosis type perineum, Feb. 72 minimal, Feb. 87
1, Feb. 92 plexiform moderate, Feb. 87
Myelodysplasia, Jan. 17-18 diffuse, Feb. 69-70, Feb. 71 neuroimaging in, Feb. 87
diffuse, as congenital, Feb. 91 oncogenes and, Feb. 98
hyperpigmentation overlying, pedigree construction in, Feb. 87
Feb. 68-69 physical examination in, Feb. 87
nodular, Feb. 69 radiography in, Feb. 87
Nail remover: ingestion of, Sept. 376 retroperitoneum, Feb. 72 retroviruses and, Feb. 98
Navicular: accessory tarsal, during retropharynx, Feb. 71-72 scoliosis in, dystrophic,
adolescence, Jan. 45 subcutaneous, Feb. 69 radiography of, Feb. 80
Neck: neurofibroma, Feb. 71-72 supraclavicular fossae, Feb. 72 sequence, Feb. 90-92
Neoplasm (see Tumor) thigh, Feb. 72 severe, Feb. 87
Nephrectomy: in polycystic kidney types, Feb. 69-70 severity, Feb. 90
disease, Nov./Dec. 447 visceral, Feb. 72 severity grades, Feb. 86-90
Nephritis Neurofibromatosis timing, Feb. 90-92
hereditary, Nov./Dec. 441 Clinical care, Feb. 67 treatment, Feb. 98
tubulointerstitial, Nov./Dec. 440 commentary, Feb. 107 vertebra in, Feb. 80-81
drugs implicated in, Nov./Dec. diagnosis, Feb. 88-89 Neurofibromatosis type 2 linkage,
440 genetic counseling, Feb. 93-95 Feb. 93
Nephrogenic diabetes insipidus, diagnosis clarification, Feb. Neurofibrosarcoma, Feb. 73-74
Nov./Dec. 443-445 93-94 enlargement in, Feb. 74
Nephrologic abnormalities: in HIV-1, prognosis and burden of, Feb. neurologic deficit in, focal, Feb. 74
Apr. 189-190 94 pain in, Feb. 73
Nephronophthisis, Nov./Dec. 446 recurrence risks, Feb. 94 Neuroimaging
Nephropathy reproductive alternatives, Feb. computerized, in
IgA, Nov./Dec. 435 94-95 neurofibromatosis, Feb.
membranous, Nov./Dec. 435-436 support, Feb. 95 95-96
Nephrotic syndrome, Nov./Dec. genomic imprinting in, Feb. 95 neurofibromatosis type 1, Feb. 87
molecular biology in, Feb. 96-99 screening of optic pathway glioma,
congenital, Nov./Dec. 440-441 natural history, Feb. 67—84 Feb. 76
IV immunoglobulin in, Sept. 338 neuroimaging, computerized, Feb. Neurologic
minimal-change, Jan. 52 95-96 disease, IV immunoglobulin in,
steroid dependents and, Aug. 328 pigmentation in, Feb. 67—69 Sept. 344
Nerve research centers, Feb. 67 examination in orthopedics, Jan.
conduction velocity studies segmental, with café au lait spots, 14
neurofibromatosis type 1, Feb. Jan. 7 Newborn, Jan. 14-23
86 self-help organizations, Feb. 99 examination, Jan. 14
optic, glioma, CT of, Feb. 74 tumors in, Feb. 69-78 extremity
Nervous system: central, in HIV-1, types of, differentiating, Feb. lower, Jan. 18-23
Apr. 186-187 88-89 upper, Jan. 14-16
Neurobehavioral deficiency: in child Neurofibromatosis type 1, Feb. screening for phenylketonuria (see
exposed to cocaine in 66-106 Phenylketonuria and newborn
pregnancy, Aug. 312-313 bowing in, Feb. 80 screening)
Neurofibroma café au lait spots in, Feb. 68 sepsis, IV immunoglobulin in,
buccal pad, Feb. 71 dysplasia in, Feb. 78-84 Sept. 340-341
buttock, Feb. 72 of extremity, lower, radiography of, sick, hospital resource allocation
cheek, Feb. 71 Feb. 79 and insurance, July 289
consequences of, Feb. 72—73 freckling in, Feb. 68 spine, Jan. 16-18
cutaneous, Feb. 69, Feb. 70 functional abnormalities in, Feb. thrombocytopenia in, alloimmune,
extremity, upper, proximal part, 84-86 Sept. 373
Feb. 72 GAP-related domain, Feb. 97 toxicologic testing for cocaine,
face, Feb. 71 gene, Feb. 96-98 Aug. 316-317
foot, Feb. 72 characterization, Feb. 96-98 Nose blowing: hearing and otitis
forearm, Feb. 72 cloning, Feb. 96-98 media, July 285
as function of age, Feb. 90-91 diagnostic testing, Feb. 98 Nursemaid’s elbow, Jan. 26
hand, Feb. 72 linkage, Feb. 96-98 Nutrition
leg, Feb. 72 therapy, Feb. 98-99 in brain development, May/June
locations, Feb. 70—73 genetics, Feb. 92-95 228-229
mediastinum, Feb. 72 linkage, Feb. 93 problems in HIV-1, Apr. 187-188
Current Problems in Pediatrics / November/December 1992 467
Nutrition Continued Otitis media Penis
requirements and weaning, radium for, Nov./Dec. 453 cancer, and circumcision,
May/June 229-231 serous, nose blowing and hearing Nov./Dec. 427
status, skin fold thickness in, Mar. in, July 285 hygiene in circumcision, Nov./Dec.
153 Otorhinolaryngologic complications: 429
of HIV-1, Apr. 188-189 Percussion: in orthopedics, Jan. 14
Overuse syndromes: during Perineum: neurofibroma, Feb. 72
Oo adolescence, Jan. 44 Perthes disease, Jan. 34
Oxalosis, Nov./Dec. 442-443 Pertussis immunization: in apnea,
Obesity, July 278-279 Oxygen May/June 242
erythrocyte sedimentation rate story in retinopathy of prematurity, Pets: for biomedical research
and, Apr. 209-210 Sept. 349-351 purposes, May/June 242
prevention and cardiovascular therapy in retinopathy of Pharmaceuticals (see Drugs)
health schedule, July 279 prematurity, Sept. 366-367 Phenylketonuria, Apr. 159-165
Obstetric performance: positive, 1Q of children with, and diet
correlation with gestational control loss, Apr. 162
age, Oct. 413 P maternal, Apr. 162-163
Occupation: and cancer, Mar. 151 newborn screening, Apr. 159-165
Oil: Arabian crude, and DNA, Oct. “Pac Man,” Mar. 150 breast-feeding and, Apr. 164
417 Pain cost, Apr. 164
Oncogenes: and neurofibromatosis back, during adolescence, facts, basic, Apr. 159
type 1, Feb. 98 Jan. 41 future uses for, Apr. 164
Oncologic disorders: IV growing, Jan. 36 impact of, Apr. 159
immunoglobulin in, Sept. 338 knee, during adolescence, Jan. 43 incidence, Apr. 160—161
Optic pathway glioma, Feb. 74-77 in neurofibrosarcoma, Feb. 73 issues, Apr. 163-164
chemotherapy of, Feb. 77 Palpation: in orthopedics, Jan. missed cases, Apr. 163
chiasmal, Feb. 75 13-14 test timing, Apr. 164
nerve, CT of, Feb. 74 Palsy treatment efficacy, Apr. 161-162
neuroimaging screening, Feb. 76 brachial plexus, obstetric, Jan. variants, Apr. 159-160
vision loss in, Feb. 76 15-16 Pheochromocytoma, Feb. 77-78
Oral neurofibroma, Feb. 71 cerebral, in toddler, Jan. 24 Physical activity: in cardiovascular
Orbit: and neurofibroma, Feb. 71 Pampers, Sept. 375 fitness, July 276-278
Orthopedics, Jan. 13-55 Paraganglioma, Feb. 78 Pigmentation in neurofibromatosis,
during adolescence, Jan. 37—45 Parasitic infections: in HIV-1, Apr. Feb. 67-69
confirmatory tests, Jan. 14 184 Pituitary
deformity, Jan. 13 Paraspinal dwarfism of Richard Ill, Mar. 149
diagnosis, Jan. 13-14 neurofibroma, Feb. 77 hypothalamic-growth cartilage
discomfort, Jan. 13 tumors, Feb. 77 axis, Oct. 398
dysfunction, Jan. 13 Parents in retinopathy of prematurity PKU (see Phenylketonuria)
history, Jan. 13 (see Retinopathy of Platelet-derived growth factor family,
inspection, Jan. 13 prematurity, parents in) Oct. 401
juvenile, Jan. 32—37 Parvovirus: IV immunoglobulin in, Playing: with fire hydrants, Feb. 108
muscle strength, Jan. 14 Sept. 342 Pneumocystis carinii pneumonia in
neurologic examination, Jan. 14 Patella HIV-1, Apr. 179-181
for newborn, Jan. 14-23 chondromalacia, during diagnosis, age at, Apr. 179
normal, Jan. 13 adolescence, Jan. 43 drug regimens, Apr. 180-181
palpation, Jan. 13-14 dislocation during adolescence, prophylaxis initiation,
percussion in, Jan. 14 Jan. 43 recommendations for, Apr.
physical examination, Jan. 13-14 subluxation during adolescence, 182
range of motion, Jan. 14 Jan. 43 Pneumonia, Pneumocystis carinii
for toddler, Jan. 24—32 Pectus excavatum: in (see Pneumocystis carinii
Ortolani’s test: in hip dysplasia, Jan. neurofibromatosis type 1, Feb. pneumonia)
19 81 Pneumonitis: lymphoid interstitial, in
Osgood-Schiatter disease: during Pediatrician HIV-1, Apr. 186
adolescence, Jan. 43-44 advocate, role of, May/June Poisoning
Osteochondritis dissecans: during 220-221 carbon monoxide, Aug. 328-329
adolescence, Jan. 44 role in health care in adolescents, lead (see Lead poisoning)
Osteochondroma: juvenile, Jari. July 254-255 Polycystic kidney disease
32-33 Pelvis: neurofibroma, Feb. 72 autosomal dominant, Nov./Dec.
Osteomyelitis Penicillamine: in retinopathy of 448
juvenile, Jan. 32 prematurity, Sept. 364-365 autosomal recessive, Nov./Dec.
in toddler, Jan. 25-26 Penicillin: causing anaphylaxis, Mar. 446-448
Osteosarcoma: juvenile, Jan. 33 133-134 Polydactyly, Jan. 15
468 Current Problems in Pediatrics / November/December 1992